On Thursday, June 9, 2016, the Antimicrobial Drugs Advisory Committee (AMDAC) supported, by a vote of 10-Yes to 5-No, with 1 abstention, the safety and efficacy of Merck’s bezlotoxumab for the proposed indication of the prevention of Clostridium difficile infection (CDI) recurrence in patients aged 18 years and older.
See the SAC Tracker report